Skip to main content
. 2020 Jul;12(7):3764–3773. doi: 10.21037/jtd-20-1882

Figure 3.

Figure 3

Drug responses of patient-derived lymph node metastatic adenocarcinoma organoids. (A) Organoid culture of lymph node metastatic adenocarcinoma; (B) dose-response curves of patient-derived lymph node metastatic adenocarcinoma organoids treated with EGFR-TKI afatinib, osimertinib, erlotinib HCl, gefitinib, and icotinib. Cell viability was measured by an ATP-based assay after 4 days of drug incubation. TKI, tyrosine kinase inhibitor.